Tarsa: Fishing in a big pond

While the osteoporosis market is dominated by large companies with established or generic products, Tarsa Therapeutics Inc. believes it can carve out a niche as a second-line therapy for patients with mild to moderate disease. The company plans to submit an NDA by year end for a recombinant oral salmon calcitonin in-licensed from Unigene Laboratories Inc.

According to CEO and co-founder David Brand, about 12 million people in the U.S. have osteoporosis or osteopenia; and about 90% have mild to moderate disease...